• Medicine
  • Published in
    Cancer epidemiology…
    1998

Aromatase inhibitors as potential cancer chemopreventives.

@article{Kelloff1998AromataseIA,
  title={Aromatase inhibitors as potential cancer chemopreventives.},
  author={Gary j. Kelloff and Ronald A. Lubet and Ronald Lieberman and K M Eisenhauer and Vernon E. Steele and James A. Crowell and Ernest T. Hawk and Charles W. Boone and Caroline C. Sigman},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={1998},
  volume={7 1},
  pages={
          65-78
        }
}
Epidemiological and experimental evidence strongly supports a role for estrogens in the development and growth of breast tumors. A role for estrogen in prostate neoplasia has also been postulated. Therefore, one chemopreventive strategy for breast and prostate cancers is to decrease estrogen production. This can be accomplished by inhibiting aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis. The use of aromatase inhibitors is of clinical interest for… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.

VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Farnesyl protein transferase inhibitors as potential cancer chemopreventives.

  • Gary j. Kelloff, Ronald A. Lubet, +4 authors Caroline C. Sigman
  • Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 1997

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

  • Gary j. Kelloff, Judith R. Fay, +4 authors Caroline C. Sigman
  • Chemistry, Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 1996
VIEW 1 EXCERPT

Enzyme-activated inhibitors of steroidal hydroxylases